contact lens high myopia
Article
Can You Not Read The Billboards Without Glasses?
By John
Many of us suffer from the problem of being unable to read things at a distance. Medically such a condition would be termed as myopia. The only option till recently was to wear glasses. The worse your eyes were, the thicker your glasses got. But those days are over now. You now have the option to rectify the condition and see things normally without the aid of glasses and contact lens.
So are you interested to learn more about lasik? Here is a gist of what it is.
Eye surgery is an abbreviation of Laser Assisted in Situ Keratomileusis. One of the various refractive eye surgeries available today has gained immense popularity after it was approved by the FDA. The main reason for the popularity of this is that it has been successful in over 95% cases with amazing results.
Apart from operation is also effective in cases of hyperopia and astigmatism. Hyperopia, also known as farsightedness, is the other way round. Astigmatism is something different where the patient has irregularities in his cornea which as a result distorts the image formed on the retina of the eye.
There are a few basic things that any optometrist will look for before a surgery. That would primarily include your eye health history. In case of a particular few diseases the chances of you undergoing a eye surgery will significantly decrease. These would include glaucoma, herpes, eye injuries or thin corneas. Any of these conditions can disqualify you as a suitable candidate for this eye surgery. Another important criterion is whether there has been an alteration in your eye wear prescription over the last year. Before a operation your eyes should be steady. If they are not then the optometrist might just postpone the surgery for a few months until he is satisfied that your eyes are ready to undergo that surgery.
The average cost for the operation of each eye is about $1,800. Of course this will vary according to the surgeon and the kind of procedure being employed. But still the average cost is a bit steep and it might be difficult for many to fund the cost of such an operation at one go. Thankfully, there are options available which a patient can utilize if it's difficult for him to pay that amount at one go. And this can be done without compromising on the quality of the operation.
Article Source: http://www.article-outlet.com/
![]() |
What To Talk With Your Beverly Hills Lasik Eye Surgeon About
By Frank Montes Here are some of the questions that you need to ask your Beverly Hills lasik eye surgeon. * What amount of pain will you be in? Depending on the exact procedure and the skill of the Read more... |
![]() |
Lasik Doctor How To Find One For You By ArvindSingh Magicians, Divine souls, God and what not, since years and years, a doctor has been called by such names. He is like a dim light in darkness that ultimately gets the brightness Read more... |
Related RSS Feeds
Article Title: Promedior Announces Initiation Of Phase 2a Of Anti-Fibrotic Therapeutic, PRM-151, In The Prevention Of Post-Surgical Scarring In Glaucoma Patients Release Date: Thu, 09 Sep 2010 01:00:00 PDT Description: Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat fibrotic and inflammatory diseases, announced that it has initiated a Phase 2a clinical study of PRM-151 to evaluate the efficacy, safety, and tolerability of PRM-151 in preventing post-surgical scarring in glaucoma patients following glaucoma filtration surgery... |
Article Title: Can-Fite BioPharma Announces The Initiation Of Phase 3 In Dry Eye Syndrome Release Date: Wed, 08 Sep 2010 07:00:00 PDT Description: Can-Fite BioPharma Ltd (TASE:CFBI), a biotechnology company traded on the Tel Aviv Stock Exchange, announced today that it has opened an Investigational New Drug application (IND) with the US-FDA for a Phase 3 study of its lead drug, CF101, in patients with moderate to severe Dry Eye Syndrome... |
Article Title: ThromboGenics Presents Positive Pooled Results From The MIVI-TRUST Phase III Program Release Date: Tue, 07 Sep 2010 00:00:00 PDT Description: ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical company focused on the discovery and development of innovative treatments for eye disease, cardiovascular disease and cancer, announces that the pooled results from the successful microplasmin MIVI-TRUST Phase III program were presented today at the EURETINA (European Society of Retina Specialists) Congress in Paris, France... |
Article Title: American Academy Of Ophthalmology Joins Forces With Middle East Africa Council Of Ophthalmology For Joint Meeting In Chicago October 16 To 19 Release Date: Mon, 06 Sep 2010 02:00:00 PDT Description: The largest and most comprehensive ophthalmic educational meeting in the world, the American Academy of Ophthalmology's (Academy) 2010 Joint Meeting in conjunction with the Middle East Africa Council of Ophthalmology (MEACO) will be taking place in Chicago, October 16 to 19... |


